newsfilter
← Latest News
GlobeNewswire·

Important Notice to Long-Term Shareholders of Boston Scientific Corporation (NYSE: BSX): Corcept Therapeutics, Inc. (NASDAQ: CORT); Nektar Therapeutics (NASDAQ: NKTR): and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your Behalf

BSXCORTNKTRUNCY
  • Grabar Law Office is investigating Boston Scientific (NYSE: BSX) for alleged breaches of fiduciary duties by officers & directors regarding false revenue projections & underestimated market risks.
  • Boston Scientific shares purchased prior to July 23, 2025, may seek corporate reforms & fund recovery, while those bought between July 23, 2025, & February 3, 2026, may join a class action.
  • The Boston Scientific investigation stems from a February 4, 2026, earnings miss that revealed competition eroded U.S. EP market share despite prior claims of 2x market growth.
  • Grabar Law Office is investigating Corcept Therapeutics (NASDAQ: CORT) for false statements regarding the strength of clinical evidence & likelihood of FDA approval for relacorilant.
  • Corcept shareholders who purchased shares prior to October 31, 2024, may seek reforms & fund recovery, with no cost to the investor.
  • The Corcept issue was revealed on December 31, 2025, when the FDA issued a Complete Response Letter rejecting the NDA due to insufficient clinical evidence.
  • Grabar Law Office is investigating Nektar Therapeutics (NASDAQ: NKTR) for misleading statements about the integrity of the REZOLVE-AA clinical trial enrollment.
  • Nektar shares purchased prior to February 26, 2025, may seek reforms & fund recovery, while those bought between February 26, 2025, & December 15, 2025, may join a class action.
  • The Nektar investigation follows a December 16, 2025, disclosure that trial failures were caused by ineligible patient enrollment, overstating trial prospects.
  • Grabar Law Office is investigating Unicycive Therapeutics (NASDAQ: UNCY) for overstating FDA manufacturing compliance readiness & regulatory prospects for oxylanthanum carbonate.
  • Unicycive shareholders who purchased shares prior to March 29, 2024, & still hold them may seek corporate reforms & fund recovery at no cost.
  • All investigations allow shareholders to contact Joshua Grabar at jgrabar@grabarlaw.com or call 267-507-6085 for more information.